Immune system plays a major role in brain damage after repeated concussions, study suggests

From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...
Greek Reporter

Human Immune Systems Are Not the Same Worldwide

A new study shows human immune systems differ across populations, raising new questions for medicine and global drug research ...
Nature

Huge Chinese cell atlas reveals surprising immune variation among peoples

A giant functional atlas of immune cells in a Chinese cohort reveals crucial differences with European and Japanese data sets ...

New tech promises to make colorful solar cells to jazz up your house

A new generation of 3D-printed solar cells could let buildings generate power through colorful, semi-transparent windows ...

Javelin Sciences Becomes the First U.S. Laboratory to Offer Testing for SARS-CoV-2 Spike Protein in Serum and Exosomes

BURTON, MI, UNITED STATES, January 9, 2026 /EINPresswire.com/ -- Javelin Sciences, a pioneering certified biotechnology ...
Fierce Pharma

Orca rides $250M funding wave toward cancer cell therapy launch

Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the ...
Contract Pharma

Autolus Therapeutics Explores the Feasibility of Adopting Cellares’ Cell Shuttle Platform

Autolus Therapeutics, a commercial-stage biopharmaceutical company, has announced plans to assess the feasibility of Cellares ...
Pharmabiz

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first ...
PharmiWeb

Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases

T-cell engagers (TCEs) have the most promising product profile across all deep B-cell depleting modalitiesCizutamig (BCMA TCE) positioned as first and best-in-class for autoimmune diseasesOver 60 ...